CMMB

Clinical Trial Results: Data from Chemomab's Phase 2 SPRING trial presented at BSG Live'25 indicates that nebokitug is a well-tolerated treatment for primary sclerosing cholangitis (PSC), showing significant improvements in biomarkers related to disease progression, particularly in patients with moderate to advanced disease.

Future Developments: The positive results support the advancement of nebokitug to a Phase 3 trial, aiming to establish it as the first approved therapy for PSC, addressing a critical unmet medical need.

FDA Alignment Achieved: Chemomab Therapeutics has received confirmation from the FDA on critical Chemistry, Manufacturing, and Controls (CMC) topics and non-clinical toxicology studies for their drug nebokitug, facilitating its Phase 3 clinical trial preparations for primary sclerosing cholangitis (PSC).

Nebokitug Overview: Nebokitug is a first-in-class monoclonal antibody targeting CCL24, showing promise in treating severe fibro-inflammatory diseases, with positive results from previous clinical trials and designations from the FDA and EMA for orphan drug status.

Kura Oncology's Stock Performance: Kura Oncology's shares have increased by 15.5% recently, following the FDA's acceptance of their new drug application for ziftomenib, a treatment for relapsed or refractory acute myeloid leukemia, with a decision expected by November 30, 2025.

Drug Development and Collaborations: Ziftomenib is positioned to be the first menin inhibitor approved for this condition, and Kura has partnered with Kyowa Kirin for its development. The company is also advancing other cancer treatments, including KO-2806 and tipifarnib, with data presentations anticipated later in 2025.